Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals?</title><author><name sortKey="Boettiger, David C" sort="Boettiger, David C" uniqKey="Boettiger D" first="David C" last="Boettiger">David C. Boettiger</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Sabin, Caroline A" sort="Sabin, Caroline A" uniqKey="Sabin C" first="Caroline A" last="Sabin">Caroline A. Sabin</name><affiliation><nlm:aff id="A2">Research Department of Infection and Population Health, UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Grulich, Andrew" sort="Grulich, Andrew" uniqKey="Grulich A" first="Andrew" last="Grulich">Andrew Grulich</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name><affiliation><nlm:aff id="A4">CHU de Bordeaux and INSERM U897, Université de Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:aff id="A5">Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="D Rminio Monforte, Antonella" sort="D Rminio Monforte, Antonella" uniqKey="D Rminio Monforte A" first="Antonella" last="D Rminio Monforte">Antonella D Rminio Monforte</name><affiliation><nlm:aff id="A6">Department of Health Sciences, San Paolo University Hospital, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Kirk, Ole" sort="Kirk, Ole" uniqKey="Kirk O" first="Ole" last="Kirk">Ole Kirk</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Phillips, Andrew" sort="Phillips, Andrew" uniqKey="Phillips A" first="Andrew" last="Phillips">Andrew Phillips</name><affiliation><nlm:aff id="A2">Research Department of Infection and Population Health, UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Bower, Mark" sort="Bower, Mark" uniqKey="Bower M" first="Mark" last="Bower">Mark Bower</name><affiliation><nlm:aff id="A7">National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="F Tkenheuer, Gerd" sort="F Tkenheuer, Gerd" uniqKey="F Tkenheuer G" first="Gerd" last="F Tkenheuer">Gerd F Tkenheuer</name><affiliation><nlm:aff id="A8">Leiter Infektiologie, Klinik I für Innere Medizin, Universitätsklinikum Köln (AöR), Köln, Germany</nlm:aff></affiliation></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26854812</idno><idno type="pmc">4889546</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889546</idno><idno type="RBID">PMC:4889546</idno><idno type="doi">10.1097/QAD.0000000000001053</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">002053</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002053</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals?</title><author><name sortKey="Boettiger, David C" sort="Boettiger, David C" uniqKey="Boettiger D" first="David C" last="Boettiger">David C. Boettiger</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Sabin, Caroline A" sort="Sabin, Caroline A" uniqKey="Sabin C" first="Caroline A" last="Sabin">Caroline A. Sabin</name><affiliation><nlm:aff id="A2">Research Department of Infection and Population Health, UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Grulich, Andrew" sort="Grulich, Andrew" uniqKey="Grulich A" first="Andrew" last="Grulich">Andrew Grulich</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Bonnet, Fabrice" sort="Bonnet, Fabrice" uniqKey="Bonnet F" first="Fabrice" last="Bonnet">Fabrice Bonnet</name><affiliation><nlm:aff id="A4">CHU de Bordeaux and INSERM U897, Université de Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:aff id="A5">Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="D Rminio Monforte, Antonella" sort="D Rminio Monforte, Antonella" uniqKey="D Rminio Monforte A" first="Antonella" last="D Rminio Monforte">Antonella D Rminio Monforte</name><affiliation><nlm:aff id="A6">Department of Health Sciences, San Paolo University Hospital, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Kirk, Ole" sort="Kirk, Ole" uniqKey="Kirk O" first="Ole" last="Kirk">Ole Kirk</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Phillips, Andrew" sort="Phillips, Andrew" uniqKey="Phillips A" first="Andrew" last="Phillips">Andrew Phillips</name><affiliation><nlm:aff id="A2">Research Department of Infection and Population Health, UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Bower, Mark" sort="Bower, Mark" uniqKey="Bower M" first="Mark" last="Bower">Mark Bower</name><affiliation><nlm:aff id="A7">National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="F Tkenheuer, Gerd" sort="F Tkenheuer, Gerd" uniqKey="F Tkenheuer G" first="Gerd" last="F Tkenheuer">Gerd F Tkenheuer</name><affiliation><nlm:aff id="A8">Leiter Infektiologie, Klinik I für Innere Medizin, Universitätsklinikum Köln (AöR), Köln, Germany</nlm:aff></affiliation></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name><affiliation><nlm:aff id="A3">CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name><affiliation><nlm:aff id="A1">The Kirby Institute, UNSW Australia, Sydney, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="ISSN">0269-9370</idno><idno type="eISSN">1473-5571</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Objective</title><p id="P1">Nelfinavir exhibits potent anti-cancer properties against a range of tumours. However, in 2006/07, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons.</p></sec><sec id="S2"><title>Design</title><p id="P2">Observational cohort study.</p></sec><sec id="S3"><title>Methods</title><p id="P3">D:A:D study data was analyzed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1/Jul/2006–30/Jun/2007.</p></sec><sec id="S4"><title>Results</title><p id="P4">A total of 42,006 individuals (50% white, 73% male) contributed 303,005 person-years of follow-up between 1/Jan/2004–1/Feb/2014. At study enrolment, median age was 40 (interquartile range [IQR] 33–46) years and 8,305 individuals had a history of nelfinavir use (median duration 1.7 [IQR 0.7–3.4] years). During follow-up, nelfinavir was used by 2,476 individuals for a median of 1.7 (IQR 0.7–3.8) years; 1,063 were exposed to nelfinavir between 1/Jul/2006–30/Jun/2007. Overall, 2,279 cancers were diagnosed at a rate of 0.75 (95% confidence interval [95%CI] 0.72–0.78) per 100 person-years. Neither greater cumulative exposure to nelfinavir (adjusted risk ratio [aRR] 0.93 for every additional 5 years, 95%CI 0.82–1.06, p=0.26) nor current use of nelfinavir (aRR 0.98 vs. other protease inhibitor use, 95%CI 0.68–1.41, p=0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1/Jul/2006–30/Jun/2007 compared to those receiving other treatment over this period was 1.07 (95%CI 0.78–1.46, p=0.68).</p></sec><sec id="S5"><title>Conclusions</title><p id="P5">Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of Feb/2014, exposure to the 2006/07 contamination of nelfinavir does not appear to be associated with increased cancer incidence.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8710219</journal-id><journal-id journal-id-type="pubmed-jr-id">1493</journal-id><journal-id journal-id-type="nlm-ta">AIDS</journal-id><journal-id journal-id-type="iso-abbrev">AIDS</journal-id><journal-title-group><journal-title>AIDS (London, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-9370</issn><issn pub-type="epub">1473-5571</issn></journal-meta><article-meta><article-id pub-id-type="pmid">26854812</article-id><article-id pub-id-type="pmc">4889546</article-id><article-id pub-id-type="doi">10.1097/QAD.0000000000001053</article-id><article-id pub-id-type="manuscript">NIHMS757218</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boettiger</surname><given-names>David C</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sabin</surname><given-names>Caroline A</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Grulich</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ryom</surname><given-names>Lene</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bonnet</surname><given-names>Fabrice</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Reiss</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>d’Arminio Monforte</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kirk</surname><given-names>Ole</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bower</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Fätkenheuer</surname><given-names>Gerd</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lundgren</surname><given-names>Jens D</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Law</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="A1">1</xref><on-behalf-of>on behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group</on-behalf-of></contrib></contrib-group><aff id="A1"><label>1</label>The Kirby Institute, UNSW Australia, Sydney, Australia</aff><aff id="A2"><label>2</label>Research Department of Infection and Population Health, UCL, London, UK</aff><aff id="A3"><label>3</label>CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Denmark</aff><aff id="A4"><label>4</label>CHU de Bordeaux and INSERM U897, Université de Bordeaux, France</aff><aff id="A5"><label>5</label>Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands</aff><aff id="A6"><label>6</label>Department of Health Sciences, San Paolo University Hospital, Milan, Italy</aff><aff id="A7"><label>7</label>National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom</aff><aff id="A8"><label>8</label>Leiter Infektiologie, Klinik I für Innere Medizin, Universitätsklinikum Köln (AöR), Köln, Germany</aff><author-notes><corresp id="cor1"><bold>Corresponding and Reprint Request Author:</bold> David C Boettiger, PhD, Biostatistician, The Kirby Institute, UNSW Australia, Level 5 Wallace Wurth Building, UNSW Australia, 2052, Australia, Tel: +61 2 9385 0859, <email>dboettiger@kirby.unsw.edu.au</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>7</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>19</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2017</year></pub-date><volume>30</volume><issue>10</issue><fpage>1629</fpage><lpage>1637</lpage><pmc-comment>elocation-id from pubmed: 10.1097/QAD.0000000000001053</pmc-comment>
<abstract><sec id="S1"><title>Objective</title><p id="P1">Nelfinavir exhibits potent anti-cancer properties against a range of tumours. However, in 2006/07, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons.</p></sec><sec id="S2"><title>Design</title><p id="P2">Observational cohort study.</p></sec><sec id="S3"><title>Methods</title><p id="P3">D:A:D study data was analyzed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1/Jul/2006–30/Jun/2007.</p></sec><sec id="S4"><title>Results</title><p id="P4">A total of 42,006 individuals (50% white, 73% male) contributed 303,005 person-years of follow-up between 1/Jan/2004–1/Feb/2014. At study enrolment, median age was 40 (interquartile range [IQR] 33–46) years and 8,305 individuals had a history of nelfinavir use (median duration 1.7 [IQR 0.7–3.4] years). During follow-up, nelfinavir was used by 2,476 individuals for a median of 1.7 (IQR 0.7–3.8) years; 1,063 were exposed to nelfinavir between 1/Jul/2006–30/Jun/2007. Overall, 2,279 cancers were diagnosed at a rate of 0.75 (95% confidence interval [95%CI] 0.72–0.78) per 100 person-years. Neither greater cumulative exposure to nelfinavir (adjusted risk ratio [aRR] 0.93 for every additional 5 years, 95%CI 0.82–1.06, p=0.26) nor current use of nelfinavir (aRR 0.98 vs. other protease inhibitor use, 95%CI 0.68–1.41, p=0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1/Jul/2006–30/Jun/2007 compared to those receiving other treatment over this period was 1.07 (95%CI 0.78–1.46, p=0.68).</p></sec><sec id="S5"><title>Conclusions</title><p id="P5">Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of Feb/2014, exposure to the 2006/07 contamination of nelfinavir does not appear to be associated with increased cancer incidence.</p></sec></abstract><kwd-group><kwd>HIV</kwd><kwd>Nelfinavir</kwd><kwd>Cancer</kwd><kwd>Ethyl mesylate</kwd><kwd>Kaposi’s sarcoma</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0020530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0020530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |